Tag: litigation

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the “Class Period”), of the important July 21, 2025 lead plaintiff deadline.

JERICHO, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- Kimco Realty Corporation (NYSE: KIM) (the “Company”) today announced that its subsidiary, Kimco Realty OP, LLC (“Kimco OP” and, together with the Company, “Kimco”), has priced a public offering of $500 million aggregate principal amount of 5.300% notes due 2036 (the “notes”) with an effective yield of 5.354%, maturing February 1, 2036. The notes will be fully and unconditionally guaranteed by the Company. The offering is expected to settle on June 26, 2025, subject to the satisfaction of customary closing conditions.

NEW PORT RICHEY, Fla., June 16, 2025 (GLOBE NEWSWIRE) -- Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo”, “Zeo Energy”, or the “Company”), a Florida-based provider of residential solar and energy efficiency solutions, today reported financial results for the first quarter ended March 31, 2025.

ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fiscal first quarter of 2025 which ended April 30, 2025.

ATHENS, Greece, June 16, 2025 (GLOBE NEWSWIRE) -- Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”), a ship-owning company providing petroleum products, crude oil, and drybulk seaborne transportation services, today announced a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Shares”), payable on June 30, 2025 to holders of record as of June 25, 2025. The dividend payment relates to the period from the last dividend payment date for the Series A Preferred Shares on March 30, 2025, through June 29, 2025.

ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against 3D Systems Corporation (“3D Systems” or the “Company”) (NYSE: DDD). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding 3D Systems’ business, operations, and compliance policies, including allegations that: (i) 3D Systems had understated the impact of weakened customer spending on the Company’s business, while overstating its resilience in challenging industry conditions; and (ii) in addition, the updated milestone criteria in the United Partnership would negatively impact the Company’s Regenerative Medicine Program revenue.

Les résultats d’études croisées de l’association ibrutinib et vénétoclax en première intention montrent un bénéfice clinique significatif pour une durée fixe, ainsi qu’une probabilité accrue de maladie résiduelle minimale indétectable et de survie sans progression par rapport à l’association acalabrutinib et vénétoclax¹

Chicago, Illinois, June 16, 2025 (GLOBE NEWSWIRE) -- Mag Mile Capital, Inc. (OTCQB: MMCP) ("Mag Mile", or the "Company") is pleased to announce the successful arrangement of $10.25 million in joint venture equity on behalf of the development team executing an innovative Class A office-to-multifamily conversion project at 111 W. Illinois in the River North neighborhood of Chicago, IL.

HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis.